Overall, our findings strongly support that circulating FABP4 is related to the ectopic lipid content in the liver, thereby proposing this molecule as a potential non-invasive tool for the diagnosis of the early stages of NAFLD in individuals at increase cardiometabolic risk. The gene discussed is FABP4; the disease is metabolic dysfunction-associated steatotic liver disease.